Teva Pharmaceutical Industries (TEVA) Notes Payables (2009 - 2017)

Teva Pharmaceutical Industries (TEVA) has reported Notes Payables for 7 consecutive years, with $1.0 million the latest figure, recorded in Q4 2017.

• For the quarter ending Q4 2017, Notes Payables fell 93.33% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2017 stood at $1.0 million (down 93.33% YoY), and the FY2017 full-year result was $1.0 million, down 93.33% from the prior year.
• Notes Payables declined to $1.0 million in Q4 2017 per TEVA's latest filing, from $15.0 million in the prior quarter.
• Across five years, Notes Payables topped out at $75.0 million in Q4 2015 and bottomed at $1.0 million in Q4 2017.
• Historically, Notes Payables has averaged $32.6 million across 4 years, with a median of $26.0 million in 2016.
• The sharpest annual moves came in 2015 and 2017: Notes Payables soared 63.04% in 2015, then plunged 93.33% in 2017.
• Over 4 years, Notes Payables stood at $46.0 million in 2014, then jumped by 63.04% to $75.0 million in 2015, then sank by 80.0% to $15.0 million in 2016, then slumped by 93.33% to $1.0 million in 2017.
• According to Business Quant data, Notes Payables over the past three periods registered $1.0 million, $15.0 million, and $26.0 million for Q4 2017, Q4 2016, and Q1 2016 respectively.